BBIO Key Statistics, Chart & Performance
The current stock price of BBIO is 76.26 USD. In the past month the price increased by 0.75%. In the past year, price increased by 125.69%.
BBIO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO is one of the better performing stocks in the market, outperforming 95.94% of all stocks.
BBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO has a bad profitability rating. Also its financial health evaluation is rather negative.
BBIO Financial Highlights
Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -4.18. The EPS decreased by -57.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.85% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BBIO Forecast & Estimates
26 analysts have analysed BBIO and the average price target is 85.79 USD. This implies a price increase of 12.5% is expected in the next year compared to the current price of 76.26.
For the next year, analysts expect an EPS growth of -15.01% and a revenue growth 125.58% for BBIO
BBIO Ownership
BBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About BBIO
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Company Info
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301 US
CEO: Neil Kumar
Employees: 728
Phone: 16503919740
BRIDGEBIO PHARMA INC / BBIO FAQ
What does BBIO do?
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 725 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
What is the current price of BBIO stock?
The current stock price of BBIO is 76.26 USD. The price decreased by -2.11% in the last trading session.
What is the dividend status of BRIDGEBIO PHARMA INC?
BBIO does not pay a dividend.
How is the ChartMill rating for BRIDGEBIO PHARMA INC?
BBIO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of BBIO stock?
BRIDGEBIO PHARMA INC (BBIO) operates in the Health Care sector and the Biotechnology industry.
Is BRIDGEBIO PHARMA INC (BBIO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBIO.
What is the market capitalization of BBIO stock?
BRIDGEBIO PHARMA INC (BBIO) has a market capitalization of 14.70B USD. This makes BBIO a Large Cap stock.